The recent progress of this phase II clinical trial in NSCLC and ovarian cancer has been slow, casting doubt on the validity of Siglec15 inhibitors in unselected cancer types (http://ir.nextcure.com/news-releases/news-release-details/nextcure-provides-interim-update-phase-2-portion-nc318). The gene discussed is SIGLEC15; the disease is ovarian carcinoma.